[go: up one dir, main page]

PE20232038A1 - 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek - Google Patents

3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek

Info

Publication number
PE20232038A1
PE20232038A1 PE2023002752A PE2023002752A PE20232038A1 PE 20232038 A1 PE20232038 A1 PE 20232038A1 PE 2023002752 A PE2023002752 A PE 2023002752A PE 2023002752 A PE2023002752 A PE 2023002752A PE 20232038 A1 PE20232038 A1 PE 20232038A1
Authority
PE
Peru
Prior art keywords
alkyl
naphthyridin
dihydro
mek inhibitors
compounds
Prior art date
Application number
PE2023002752A
Other languages
English (en)
Inventor
Shelley Allen
James Francis Blake
Sydney Taylor Blanche
Mark Laurence Boys
Wesley Dewit Clark
Connor James Cowdrey
Joshua Ryan Dahlke
Barbour Patrick Michael Doerner
Alex Andrew Kellum
Ellen Margaret Knapp
David Austin Moreno
Jacob Matthew O'leary
Li Ren
Faith Elizabeth Witkos
Jennifer Lynn Fulton
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20232038A1 publication Critical patent/PE20232038A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a compuestos de Formula I en donde R1 es H, Br, C1-C6 alquilo o fenilo; R2 es H, halogeno o CH3-; R3 es hidroxiC1-C6 alquil- o (C3-C6 cicloalquil)C1-C6 alcoxi-; R4 es fenilo sustituido con 1,2 o 3 sustituyentes seleccionados de fluoroC1-C6 alcoxi o C1-C6 alquil- C(=O)-; y Ra y Rb se seleccionan independientemente de fluoroC1-C6 alquilo o C1-C6 alquil-C(=O)-. Los presentes compuestos se seleccionan de 8-((4-bromo-2-fluorofenil)amino)-2-ciclopropil-7-metil-3,4-dihidro-2,7-naftiridin-1,6(2H,7H)-diona. Asimismo, se mencionan composiciones farmaceuticas que comprenden dichos compuestos y al menos un excipiente farmaceuticamente aceptable, metodos y usos como inhibidores de MEK para el tratamiento del cancer. Tambien, refiere a formas solidas de 8-((2-fluoro-4-(metiltio)fenil)amino)-2-(2-hidroxietoxi)-7-metil-3,4-dihidro-2,7-naftiridin-1,6(2H,7H)-diona o sales de las mismas.
PE2023002752A 2021-03-31 2022-03-30 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek PE20232038A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163168456P 2021-03-31 2021-03-31
US202263309346P 2022-02-11 2022-02-11
PCT/IB2022/052952 WO2022208391A1 (en) 2021-03-31 2022-03-30 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors

Publications (1)

Publication Number Publication Date
PE20232038A1 true PE20232038A1 (es) 2023-12-21

Family

ID=81308057

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002752A PE20232038A1 (es) 2021-03-31 2022-03-30 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek

Country Status (18)

Country Link
US (4) US11802127B2 (es)
EP (1) EP4313981A1 (es)
JP (1) JP7466795B2 (es)
KR (1) KR102681641B1 (es)
AU (1) AU2022250102B2 (es)
CA (1) CA3215293A1 (es)
CL (1) CL2023002896A1 (es)
CO (1) CO2023012682A2 (es)
CR (1) CR20230455A (es)
DO (1) DOP2023000208A (es)
EC (1) ECSP23073404A (es)
IL (1) IL305978A (es)
MX (1) MX2023011628A (es)
PE (1) PE20232038A1 (es)
TW (1) TWI825637B (es)
UY (1) UY39701A (es)
WO (1) WO2022208391A1 (es)
ZA (1) ZA202309566B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI825637B (zh) * 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
BR112023019861A2 (pt) 2021-03-31 2023-11-07 Xinthera Inc Inibidores de mk2 e usos dos mesmos
JP2024047569A (ja) * 2022-09-26 2024-04-05 ファイザー・インク Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413005A (pt) 2003-07-29 2006-09-26 Irm Llc compostos e composições como inibidores da proteìna cinase
US7390820B2 (en) * 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
UA84175C2 (ru) 2003-11-19 2008-09-25 Аррей Байофарма Инк. Гетероциклические ингибиторы мэк и их применение
KR100703068B1 (ko) 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
EP1761528B1 (en) * 2004-06-11 2008-01-09 Japan Tobacco, Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
AU2006299902B2 (en) 2005-05-18 2012-11-01 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
ES2569677T3 (es) 2006-03-16 2016-05-12 Second Genome, Inc. Compuestos bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
DK1937643T3 (en) 2006-03-16 2016-10-10 Second Genome Inc Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf
CA2645652A1 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20100298285A1 (en) 2006-03-16 2010-11-25 Kelly Michael G Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US8093265B2 (en) 2007-03-09 2012-01-10 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JP5363350B2 (ja) * 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
TW200938542A (en) 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2013033981A1 (zh) * 2011-09-06 2013-03-14 江苏先声药物研究有限公司 一类2,7-萘啶衍生物及其制备方法和应用
TR201811976T4 (tr) 2012-03-14 2018-09-21 Lupin Ltd Mek inhibitörleri olarak heterosiklil bileşikleri.
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
CA3008312A1 (en) 2016-01-06 2017-07-13 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
CA3078565A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
US10358447B2 (en) 2017-12-04 2019-07-23 Arbutus Biopharma Corporation Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same
WO2020072492A1 (en) 2018-10-02 2020-04-09 Baruch S. Blumberg Institute Benzamide derivatives as cgas-sting pathway agonists
CN114341124B (zh) 2018-10-17 2024-09-20 Array生物制药公司 蛋白质酪氨酸磷酸酶抑制剂
CN113645964B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
PE20220141A1 (es) 2019-04-02 2022-01-27 Array Biopharma Inc Inhibidores de la proteina tirosina fosfatasa
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
TWI825637B (zh) * 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮

Also Published As

Publication number Publication date
KR20230146655A (ko) 2023-10-19
DOP2023000208A (es) 2023-10-31
JP7466795B2 (ja) 2024-04-12
US20240002384A1 (en) 2024-01-04
MX2023011628A (es) 2023-10-13
TWI825637B (zh) 2023-12-11
US20250263411A1 (en) 2025-08-21
EP4313981A1 (en) 2024-02-07
JP2024512624A (ja) 2024-03-19
CA3215293A1 (en) 2022-10-06
US11691973B2 (en) 2023-07-04
US11802127B2 (en) 2023-10-31
AU2022250102B2 (en) 2024-05-16
AU2022250102A1 (en) 2023-10-05
BR112023019849A2 (pt) 2023-11-07
US20220324861A1 (en) 2022-10-13
WO2022208391A1 (en) 2022-10-06
CO2023012682A2 (es) 2023-10-09
KR102681641B1 (ko) 2024-07-05
ZA202309566B (en) 2024-06-26
IL305978A (en) 2023-11-01
ECSP23073404A (es) 2023-10-31
TW202304903A (zh) 2023-02-01
CR20230455A (es) 2024-01-08
CL2023002896A1 (es) 2024-02-02
UY39701A (es) 2022-10-31
US20230120188A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
PE20232038A1 (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20250850A1 (es) Compuestos macrociclicos para el tratamiento de cancer
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
EP4295852A3 (en) Piperidine derivatives as inhibitors of cyclin dependent kinase 7 (cdk7)
MX2021009763A (es) Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
PE20040411A1 (es) Compuestos de aril cetona pirrolo triazina
UY28578A1 (es) Derivados de amida
CO5580770A2 (es) Compuestos de quinolina terapeuticos con propiedades antagonistas de 5-ht
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
PE20210398A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR119728A1 (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
AR115015A1 (es) Derivados de azaespiro piperazina
CO2024012060A2 (es) Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos
NZ761680A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
CO2024011857A2 (es) Compuestos de uracilo n3-sustituidos como inhibidores de trpa1
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR126500A1 (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
CO2022000118A2 (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
ECSP034619A (es) Derivados de pirimidina